Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. - Wikidata - awgldk - TriplyDB

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q35242565

about

Role of bile acids in the regulation of the metabolic pathways Pathophysiological role of host microbiota in the development of obesity Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective.Fatty liver diseases, bile acids, and FXR Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis American Diabetes Association and JDRF Research Symposium: Diabetes and the Microbiome Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation.Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation.Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet Perilipin-2 Modulates Lipid Absorption and Microbiome Responses in the Mouse Intestine.Gut-liver axis, nutrition, and non-alcoholic fatty liver disease Antioxidant Drug Tempol Promotes Functional Metabolic Changes in the Gut Microbiota Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention Diet-microbiota interactions as moderators of human metabolism.An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.Personalized microbiome-based approaches to metabolic syndrome management and prevention.Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease.An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.Gut Microbiota in Cardiovascular Health and Disease.Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction Nutritional modulation of gut microbiota - the impact on metabolic disease pathophysiology Tryptophan-induced pathogenesis of breast cancer Non-alcoholic fatty liver and the gut microbiota.Antibiotic effects on gut microbiota and metabolism are host dependent.Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact.Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis.Molecular basis of alcoholic fatty liver disease: From incidence to treatment.Western Diet-Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment.Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

P2860

Q26738976-4214D160-F60C-4D22-AA5A-34C9A4701812 Q26750893-2FF077D3-0CF0-4952-AD87-AF6E39F42A94 Q26751258-8C55B97A-7141-43F9-9CC9-1586C7502335 Q26752614-9A3DD6F1-33A6-4191-9ADC-902BB9A37AB5 Q26753047-82CE5A81-3287-4879-A812-AA2092F8C047 Q27693345-05CE8464-7136-4CC6-A0D7-EDAB384D3B1E Q28068199-3B031072-4D55-4CAD-87AE-14A9D978251B Q28547365-9DFD07C6-610C-4050-A916-4942C24BC68B Q28602363-D1453A68-7D7A-4DC6-90BD-45A9162131BE Q28821039-383DEE6F-A595-4527-B845-85E44DAAC587 Q33578966-1F290977-5565-49CA-8C18-6457CDBDB5AD Q33687018-18909004-EEB5-4FBE-B93B-D424640AB214 Q33711736-7B9B72F1-EE84-4E04-B0BB-484171979DA0 Q35576758-309E9D29-5319-4659-9E4B-94A3BD79681A Q35613153-3A0702D4-C741-4114-AC33-6C2C91CDE6D2 Q35683242-4E8F1958-594D-45EE-A417-EDB1E3D7BAF8 Q35685083-1F52D863-744E-4A51-880D-8749BAA11A7A Q35876212-F869B464-D64D-40E5-91BC-F51B6F1B00C3 Q35956826-CA9C7AC2-0D1C-4EB1-AB96-F66CB6A28CDF Q36069065-F95CE5C9-4A12-4403-B2E1-90886EFC34CB Q36136449-528E07B2-D75A-4E68-9E70-F26ADFCDEF2D Q36148926-470D4EA4-B170-4767-B15B-C307F8E19093 Q36175953-385852A0-3E47-4803-83A4-C8D6A148A341 Q36245966-7B315077-3421-4440-8306-53C2BDE18A90 Q36287039-0FFD0196-3A37-4990-A5CB-D3E34409B832 Q36329055-0DEE3307-7ADF-4015-B640-5A686EE63811 Q36339964-7A7C639B-1AFB-4B31-BB11-77D773D10C94 Q36379436-C6CE858B-6EE8-497C-8B9C-132D97281C69 Q36590565-6740A3F7-5749-4A02-A754-48BDC2EE1E73 Q36612713-4CF5A7DD-7C5E-49BE-9133-FBF6229633A8 Q37215934-BEA0188D-E028-42DE-9BF8-C5918643A65D Q37452266-3144B8A9-DF5B-4EA4-AA46-AD44331E11BD Q37486151-9A847AC7-3454-4C28-881F-AD1D5B83BAC6 Q37538343-0B206B8C-6EF9-48E7-9D90-2F88536EFAED Q38538187-94F5AF1C-1601-4DC3-A057-7DC0284106AD Q38541491-30BB8F82-0EB5-4E60-A5B4-82D0DA22EB1B Q38572366-B223E470-0C78-40F6-AB69-CFA7127CD579 Q38595071-EBA0A137-03D3-408A-90AE-B98DC0296402 Q38677715-C4E24EFE-FA38-4BD9-9871-6F6066836909 Q38711424-D78F2B24-2CE4-4AEC-9B2D-140A590FD6E7

P2860

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q35242565

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

@ast

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

@en

type

label

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

@ast

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

@en

prefLabel

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

@ast

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

@en

P1433

Q35242565-01E4CD93-BFFB-4DFC-9FFA-7BFCEA022CB5

P1476

Q35242565-7AB41B05-5D76-439C-A7D7-BA64295BAEAF

P2093

Q35242565-056C62D5-4DF0-41AB-8C12-9059F6C31995

Q35242565-0CADC626-D878-4D5E-9497-3B33A0877F18

Q35242565-224E649B-5F9A-4EF3-A80C-5635EDE44AC2

Q35242565-6CAC0983-54A9-4D91-B637-D40E9BF15303

Q35242565-70E8EAB7-52D6-4771-B18A-59C954AC64B7

Q35242565-85FECD88-B5D8-4DF9-B7AB-2460EAA1C2DC

Q35242565-9AD6F7E0-2787-4F16-9345-B6F5BFD0A568

Q35242565-A624EFEC-3FBA-404B-A646-8E5CC14E660B

Q35242565-C6307812-7F35-4435-869C-F91C0A79A202

Q35242565-CE72B0A4-94B4-4F47-9FF6-5E71872A1402

P2860

Q35242565-094024C0-2B32-46A7-91DE-4766684CF611

Q35242565-0E15287C-996C-42EE-A580-B2FADB5F3164

Q35242565-1347466C-A639-4659-92BE-35A19C58B211

Q35242565-175FBA20-0C2B-4C9E-9956-C89A4ED56725

Q35242565-1B4C2A14-09F9-4A51-BC7C-A74A372268D6

Q35242565-1BB6EADB-65FB-4C6B-B402-41CF679E0622

Q35242565-1D9347F1-ABFC-40F0-8F37-2816D87888E9

Q35242565-28CFBE06-73F4-466E-9270-887BF7958B66

Q35242565-2A5EB1B3-141E-4820-BF4C-889141F431E5

Q35242565-2B7A052B-C8E0-4EBD-B68E-B1D031A4A821

P304

Q35242565-83E9C3A7-BF1C-4E24-B824-B5B40B7F36ED

P31

Q35242565-6D8C6E4E-5C38-4B5A-B397-5A9CA53C3768

P356

Q35242565-86B5D868-7DBC-4ED3-B0D1-1AF067BD0095

P407

Q35242565-F9BD2782-FEB5-43A9-87C3-CF71BDBDAAAF

P433

Q35242565-993B22D1-DB2B-4898-AAA3-104D5A4C9120

P478

Q35242565-E876AD5B-5624-41FF-B53D-0DA5C43B4229

P50

Q35242565-080CE915-473C-49C6-BA1A-9B8EBCFB5D6F

Q35242565-553659D4-1298-42D3-9D29-622831C0884A

Q35242565-68FD901C-13B7-4F75-8553-307F5B3FB3A8

Q35242565-9F78E33C-815A-4538-8BAC-860D052A88D6

P577

Q35242565-536D5836-06F8-455B-B31B-2F0999030060

P698

Q35242565-3921BADF-8247-42A5-8CF0-4164581FDEAE

P932

Q35242565-FF38D48D-9FD9-498F-A66C-81630483C270

P356

P1433

Journal of Clinical Investigation

P1476

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

@en

P2093

Cen Xie

http://www.w3.org/2001/XMLSchema#string

Dhimant Desai

http://www.w3.org/2001/XMLSchema#string

Fei Li

http://www.w3.org/2001/XMLSchema#string

Frank J Gonzalez

http://www.w3.org/2001/XMLSchema#string

Kristopher W Krausz

http://www.w3.org/2001/XMLSchema#string

Limin Zhang

http://www.w3.org/2001/XMLSchema#string

Naoki Tanaka

http://www.w3.org/2001/XMLSchema#string

Robert G Nichols

http://www.w3.org/2001/XMLSchema#string

Shantu G Amin

http://www.w3.org/2001/XMLSchema#string

Shogo Takahashi

http://www.w3.org/2001/XMLSchema#string

P2860

Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression

Bile acids: regulation of synthesis

Mechanisms underlying the resistance to diet-induced obesity in germ-free mice

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

FXR signaling in the enterohepatic system

An obesity-associated gut microbiome with increased capacity for energy harvest

The gut microbiota as an environmental factor that regulates fat storage

FXR is a molecular target for the effects of vertical sleeve gastrectomy

Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine

P304

386-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI76738

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Patterson

P577

2014-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25500885

http://www.w3.org/2001/XMLSchema#string

P932

4382255

http://www.w3.org/2001/XMLSchema#string